Jefferies Group reissued their buy rating on shares of Indivior (LON:INDV) in a report released on Wednesday morning. Jefferies Group currently has a GBX 500 ($6.78) price objective on the specialty pharmaceutical company’s stock.
A number of other brokerages have also weighed in on INDV. Royal Bank of Canada restated an outperform rating and issued a GBX 500 ($6.78) price objective on shares of Indivior in a report on Friday, December 1st. Morgan Stanley restated an equal weight rating and issued a GBX 410 ($5.56) price objective on shares of Indivior in a report on Friday, December 1st. Citigroup upgraded shares of Indivior to a buy rating and raised their price objective for the company from GBX 280 ($3.80) to GBX 490 ($6.64) in a report on Wednesday, November 8th. Finally, Numis Securities restated a buy rating and issued a GBX 640 ($8.68) price objective on shares of Indivior in a report on Thursday, November 30th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Indivior presently has an average rating of Buy and a consensus price target of GBX 476.43 ($6.46).
Shares of Indivior (LON INDV) opened at GBX 401 ($5.44) on Wednesday. Indivior has a fifty-two week low of GBX 246.50 ($3.34) and a fifty-two week high of GBX 421.50 ($5.72). The firm has a market cap of $2,890.00 and a price-to-earnings ratio of 1,542.31.
Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.